| pubmed-article:1918953 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C0069535 | lld:lifeskim |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:1918953 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:1918953 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:1918953 | pubmed:dateCreated | 1991-10-28 | lld:pubmed |
| pubmed-article:1918953 | pubmed:abstractText | Endothelial cells produce immunomodulatory cytokines in response to soluble mediators of inflammatory/immune reactions. We have previously demonstrated that the leukocyte-derived cytokine, oncostatin M (Onco M) can alter endothelial cell morphology, regeneration, and fibrinolytic activity in vitro. Here we demonstrate that Onco M stimulates the production of the pleiotropic cytokine, IL-6, in cultured human endothelial cells (HEC) in a time- and dose-dependent manner. Specific antibodies to IL-6 neutralize the growth-inhibitory activity for human breast carcinoma cells that is secreted by HEC in response to Onco M treatment. Specific immunoassays indicate greater than 10-fold increases in the IL-6 content of culture supernatants as early as 6 h post-treatment with Onco M (ED50 = 17 pM). This stimulation of IL-6 production by Onco M is associated with a sevenfold increase in intracellular levels of IL-6 mRNA. IL-1 alpha and TNF-alpha are also potent inducers of IL-6 production in these cells, the order of potency being IL-1 alpha greater than Onco M greater than TNF-alpha. TNF-alpha, but not IL-1 alpha, synergizes with Onco M to augment IL-6 production in HEC. HEC are 10 to 20 times more responsive to Onco M than are other nonendothelial cell types. In addition, HEC express 10 to 20 times greater numbers of high affinity cell-surface receptors for Onco M than do other nonendothelial cell types. Based on these findings, we propose that Onco M may represent a new immunomodulator regulating cytokine-induced gene products in endothelial cells. | lld:pubmed |
| pubmed-article:1918953 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1918953 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918953 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1918953 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1918953 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:1918953 | pubmed:author | pubmed-author:BrownT JTJ | lld:pubmed |
| pubmed-article:1918953 | pubmed:author | pubmed-author:ShoyabMM | lld:pubmed |
| pubmed-article:1918953 | pubmed:author | pubmed-author:CoxP MPMJr | lld:pubmed |
| pubmed-article:1918953 | pubmed:author | pubmed-author:RoweJ MJM | lld:pubmed |
| pubmed-article:1918953 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1918953 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:1918953 | pubmed:volume | 147 | lld:pubmed |
| pubmed-article:1918953 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1918953 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1918953 | pubmed:pagination | 2175-80 | lld:pubmed |
| pubmed-article:1918953 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:meshHeading | pubmed-meshheading:1918953-... | lld:pubmed |
| pubmed-article:1918953 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1918953 | pubmed:articleTitle | Regulation of IL-6 expression by oncostatin M. | lld:pubmed |
| pubmed-article:1918953 | pubmed:affiliation | Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121. | lld:pubmed |
| pubmed-article:1918953 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918953 | lld:pubmed |
